

## Centers for Medicare & Medicaid Services

**Print Message:** If you are experiencing issues printing this page, then please click 'Return to Previous Page' and select the **Need a PDF?** Button. You can now print the page from the new popup window.

[Back to Local Coverage Determinations \(LCDs\)](#)

### Local Coverage Determination (LCD): MoldX: APC and MUTYH Gene Testing (L36884)

#### - Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Noridian Healthcare Solutions, LLC	A and B MAC	02101 - MAC A	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02102 - MAC B	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02201 - MAC A	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02202 - MAC B	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02301 - MAC A	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02302 - MAC B	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02401 - MAC A	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	02402 - MAC B	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	03101 - MAC A	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03102 - MAC B	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03201 - MAC A	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03202 - MAC B	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03301 - MAC A	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03302 - MAC B	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03401 - MAC A	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03402 - MAC B	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03501 - MAC A	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03502 - MAC B	J - F	Utah

Noridian Healthcare Solutions, LLC	A and B MAC	03601 - MAC A	J - F	Wyoming
Noridian Healthcare Solutions, LLC	A and B MAC	03602 - MAC B	J - F	Wyoming

## - LCD Information

### Document Information

**LCD ID**  
L36884

**LCD Title**

MoIDX: APC and MUTYH Gene Testing

**Proposed LCD in Comment Period**

N/A

**Source Proposed LCD**

DL36884

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**

CPT only copyright 2002-2017 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association ("AHA"), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA." Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

**Original Effective Date**

For services performed on or after  
05/15/2017

**Revision Effective Date**

For services performed on or after  
05/15/2017

**Revision Ending Date**

N/A

**Retirement Date**

N/A

**Notice Period Start Date**

03/30/2017

**Notice Period End Date**

05/14/2017

### CMS National Coverage Policy

Title XVIII of the Social Security Act, §1862(a)(1)(A). Allows coverage and payment for only those services that are considered to be reasonable and necessary.

Title XVIII of the Social Security Act, §1833(e). Prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

42 Code of Federal Regulations (CFR) 410.32(a). Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

CMS On-Line Manual, Publication 100-02, *Medicare Benefit Policy Manual*, Chapter 15, §§80.0, 80.1.1, 80.2. Clinical Laboratory services.

CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) "Reporting ICD Diagnosis and Procedure Codes".

### Coverage Guidance

## Coverage Indications, Limitations, and/or Medical Necessity

This policy provides Medicare coverage for APC and MUTYH gene testing for individuals suspected to have Familial Adenomatous Polyposis (FAP), Attenuated FAP (AFAP) or MYH-associated polyposis (MAP) with a personal history of  $\geq 20$  adenomas over a lifetime.

## Summary of Evidence

FAP and AFAP are autosomal dominant syndromes caused by a germ-line mutation in the APC gene. The distinction between FAP and AFAP is largely based on the number of polyps present. Individuals with  $>100$  are said to have FAP, while those with  $<100$  are said to have AFAP. FAP affected individuals generally develop adenomas throughout the colon beginning in their teens, whereas individuals with AFAP frequently have a right-sided distribution to polyps. The average age of symptomatic FAP diagnosis ranges from 35-45 years of age<sup>1</sup>. The clinical expression of AFAP is more variable with adenomas developing at a later age, and some patients with  $<10$  cumulative adenomatous polyps<sup>2</sup>. With nearly 100% penetrance of the APC gene, colorectal cancer (CRC) is inevitable in patients with FAP if colectomy is not performed. The cumulative risk of CRC cancer in AFAP is estimated to be nearly 70% at age 80<sup>3</sup>, with up to 30% of cancers occurring over age 40<sup>4</sup>. The average age of CRC diagnosis is  $>50$  years for AFAP. FAP accounts for up to 1% of colorectal cancers.

Additional findings may be associated with classical FAP including congenital hypertrophy of retinal pigment epithelium (CHRPE); osteomas, supernumerary teeth, and odontomas; desmoids and epidermoid cysts; duodenal and other small bowel adenomas; gastric fundic gland polyps; and increased risk for medulloblastoma, papillary carcinoma of the thyroid and hepatoblastoma; and pancreatic, gastric and duodenal cancers. Although upper GI findings, thyroid and duodenal cancer risks are similar to classical FAP, other extraintestinal manifestations, including CHRPE and desmoids are unusual in AFAP.

Mutations in the MUTYH gene cause MUTYH-Associated Polyposis syndrome (MAP). Affected individuals have large numbers of adenomatous polyp, similar to patient with AFAP, and a high risk for CRC. The average age of patients with MAP-associated CRC is  $>50$  years, with nearly 25% of patients diagnosed after age 60<sup>6</sup>. Individuals with MUTYH mutations also may develop extra-colonic findings including duodenal polyps and duodenal cancer.

Treatment and surveillance recommendations for FAP, AFAP and MAP are available in the current NCCN Genetic/Familial High-Risk Assessment: Colorectal guidelines<sup>5</sup>.

## Analysis of Evidence (Rationale for Determination)

*Level of Evidence:*

Quality – High

Strength – Good

Weight - Good

Based on the results of multiple studies and the surveillance and treatment recommendations of at least one national society guideline, APC and MUTYH gene testing is reasonable and necessary for individuals suspected to have Familial Adenomatous Polyposis (FAP), Attenuated FAP (AFAP) or MYH-associated polyposis (MAP) with a personal history of  $\geq 20$  adenomas over a lifetime.

## - Coding Information

### Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

999x	Not Applicable
------	----------------

### Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

#### CPT/HCPCS Codes

##### Group 1 Paragraph:

N/A

##### Group 1 Codes:

81201	APC (ADENOMATOUS POLYPOSIS COLI) (EG, FAMILIAL ADENOMATOSIS POLYPOSIS [FAP], ATTENUATED FAP) GENE ANALYSIS; FULL GENE SEQUENCE
81202	APC (ADENOMATOUS POLYPOSIS COLI) (EG, FAMILIAL ADENOMATOSIS POLYPOSIS [FAP], ATTENUATED FAP) GENE ANALYSIS; KNOWN FAMILIAL VARIANTS
81203	APC (ADENOMATOUS POLYPOSIS COLI) (EG, FAMILIAL ADENOMATOSIS POLYPOSIS [FAP], ATTENUATED FAP) GENE ANALYSIS; DUPLICATION/DELETION VARIANTS
81403	MOLECULAR PATHOLOGY PROCEDURE, LEVEL 4 (EG, ANALYSIS OF SINGLE EXON BY DNA SEQUENCE ANALYSIS, ANALYSIS OF >10 AMPLICONS USING MULTIPLEX PCR IN 2 OR MORE INDEPENDENT REACTIONS, MUTATION SCANNING OR DUPLICATION/DELETION VARIANTS OF 2-5 EXONS)
81406	MOLECULAR PATHOLOGY PROCEDURE, LEVEL 7 (EG, ANALYSIS OF 11-25 EXONS BY DNA SEQUENCE ANALYSIS, MUTATION SCANNING OR DUPLICATION/DELETION VARIANTS OF 26-50 EXONS, CYTOGENOMIC ARRAY ANALYSIS FOR NEOPLASIA)
81435	HEREDITARY COLON CANCER DISORDERS (EG, LYNCH SYNDROME, PTEN HAMARTOMA SYNDROME, COWDEN SYNDROME, FAMILIAL ADENOMATOSIS POLYPOSIS); GENOMIC SEQUENCE ANALYSIS PANEL, MUST INCLUDE SEQUENCING OF AT LEAST 10 GENES, INCLUDING APC, BMPR1A, CDH1, MLH1, MSH2, MSH6, MUTYH, PTEN, SMAD4, AND STK11
81479	UNLISTED MOLECULAR PATHOLOGY PROCEDURE

#### ICD-10 Codes that Support Medical Necessity

##### Group 1 Paragraph:

N/A

##### Group 1 Codes:

ICD-10 CODES	DESCRIPTION
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified

C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
D12.0	Benign neoplasm of cecum
D12.1	Benign neoplasm of appendix
D12.2	Benign neoplasm of ascending colon
D12.3	Benign neoplasm of transverse colon
D12.4	Benign neoplasm of descending colon
D12.5	Benign neoplasm of sigmoid colon
D12.6	Benign neoplasm of colon, unspecified
D12.7	Benign neoplasm of rectosigmoid junction
D12.8	Benign neoplasm of rectum
Z85.038	Personal history of other malignant neoplasm of large intestine
Z86.010	Personal history of colonic polyps

#### ICD-10 Codes that DO NOT Support Medical Necessity

N/A

#### ICD-10 Additional Information

#### - General Information

##### Associated Information

N/A

##### Sources of Information

N/A

##### Bibliography

1. Jasperson KW, Burt RW. APC-Associated Polyposis Conditions. 1998 Dec 18 [Updated 2014 Mar 27]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. <http://www.ncbi.nlm.nih.gov/books/NBK1345/>
2. Burt RW, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. *Gastroenterology*. 2004 Aug;127(2):444-51. PubMed PMID: 15300576.
3. Neklason DW, et al. American founder mutation for attenuated familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2008 Jan;6(1):46-52. Epub 2007 Dec 11. PubMed PMID: 18063416.
4. Nielsen M, et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. *Clin Genet*. 2007 May;71(5):427-33. PubMed PMID: 17489848.
5. NCCN® Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Colorectal. Version 1.2016, Accessed 8/2/16 at [www.nccn.org](http://www.nccn.org).
6. Lubbe SJ, et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. *J Clin Oncol*. 2009 Aug 20;27(24):3975-80. doi: 10.1200/JCO.2008.21.6853. Epub 2009 Jul 20. PubMed PMID: 19620482.

#### - Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION	REASON(S) FOR CHANGE

05/15/2017	R1	LCD is revised to add ICD-10 code D12.0, effective 5/12/17 and to add the following required fields: Summary of Evidence, Bibliography and Analysis of Evidence.	<ul style="list-style-type: none"> <li>• Creation of Uniform LCDs Within a MAC Jurisdiction</li> <li>• Revisions Due To ICD-10-CM Code Changes</li> </ul>
------------	----	--	---

[Back to Top](#)

## - Associated Documents

### Attachments

N/A

### Related Local Coverage Documents

Article(s)

A55464 - Response to Comments: MoIDX: APC and MUTYH Gene Testing

LCD(s)

DL36884 - MoIDX: APC and MUTYH Gene Testing

### Related National Coverage Documents

N/A

### Public Version(s)

Updated on 08/15/2017 with effective dates 05/15/2017 - N/A

Updated on 03/17/2017 with effective dates 05/15/2017 - N/A

## - Keywords

- 81201
- 81202
- 81203
- 81403
- 81406
- 81435
- 81479
- APC
- MUTYH Gene
- Familial
- Adenomatous
- Polyposis
- Attenuated

Read the **LCD Disclaimer**